We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Exelixis Inc | NASDAQ:EXEL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54 | -6.54% | 21.925 | 21.77 | 21.93 | 22.24 | 20.69 | 21.64 | 7,471,580 | 22:27:13 |
From May 2019 to May 2024
By Colin Kellaher
Bristol-Myers Squibb Co. and Exelixis Inc. on Monday said a pivotal phase 3 study evaluating Opdivo in combination with Cabometyx compared to sunitinib in previously untreated advanced or metastatic renal-cell carcinoma met its key endpoints.
The companies said the study met the primary endpoint of progression-free survival at final analysis, along with the secondary endpoints of overall survival at a pre-specified interim analysis and objective response rate.
The companies said the combination Bristol's Opdivo and Exelixis' Cabometyx showed a favorable safety profile and could become an important new first-line option for patients with metastatic renal-cell carcinoma, the most common type of kidney cancer in adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 20, 2020 07:35 ET (11:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Exelixis Chart |
1 Month Exelixis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
